Approval · Notice of Compliance 10372 · 2009

ABILIFY: Notice of Compliance 10372

Issued July 9, 2009

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 10372
Date: July 9, 2009
Company: Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: New Active Substance (NAS)
Therapeutic class: Antipsychotic

Products in this notice

Brand	DIN	Status today
ABILIFY	02322374	Marketed
ABILIFY	02322382	Marketed
ABILIFY	02322390	Marketed
ABILIFY	02322404	Marketed
ABILIFY	02322412	Marketed
ABILIFY	02322455	Marketed

Medicinal ingredients

ARIPIPRAZOLE 2 MG per TAB
ARIPIPRAZOLE 5 MG per TAB
ARIPIPRAZOLE 10 MG per TAB
ARIPIPRAZOLE 15 MG per TAB
ARIPIPRAZOLE 20 MG per TAB
ARIPIPRAZOLE 30 MG per TAB